AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9764982
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (alpha-interferon plus ofloxacin)
Trial: 7844205
Drug: Low-dose step-down
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose step-down hormone replacement therapy (HRT)
Trial: 3042355
Drug: Urapidil (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (combination therapy)
Trial: 3042355
Drug: Prazosin (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (combination therapy)
Trial: 29945395
Drug: Huazhuo Jiedu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huazhuo Jiedu formula, 1 dose/day for 6 months
Trial: 22828090
Drug: Aliskiren/amlodipine/HCT 150/5/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren/amlodipine/HCT 150/5/12.5 mg (week 4)
Trial: 22828090
Drug: Aliskiren/amlodipine/HCT 300/10/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren/amlodipine/HCT 300/10/25 mg (week 8)
Trial: 22828090
Drug: Aliskiren/amlodipine/HCT 150/5/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren/amlodipine/HCT 150/5/12.5 mg (week 2)
Trial: 22828090
Drug: Dual combinations
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual combinations (aliskiren/amlodipine 150/5 mg, aliskiren/HCT 150/12.5 mg, amlodipine/HCT 5/12.5 mg)
Trial: 22828090
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination (aliskiren/amlodipine/HCT)
Trial: 19765266
Drug: Calcineurin inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitor (Control)
Trial: 18348746
Drug: r-hLH/r-hFSH (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hLH/r-hFSH (fixed combination)
Trial: 15888156
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x weekly treatment
Trial: 15888156
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x weekly treatment
Trial: 15888156
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x weekly treatment
Trial: 10353862
Drug: Thalidomide 200
RxNorm normalized name: thalidomide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 200 mg/day for 4 weeks
Trial: 8943671
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (cisplatin 120 mg/m2 and etoposide 100 mg/m2 i.v. for 3 days, every fourth week) followed by radiotherapy (56 Gy to the chest)
Trial: 29165598
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg)
Trial: 26475347
Drug: EMLA (local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA (local anesthetic cream)
Trial: 24172652
Drug: Antibiotic pomade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic pomade with bandage (control)
Trial: 23109694
Drug: Lanreotide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide (30 mg injection)
Trial: 17963528
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for mild gestational diabetes mellitus (dietary advice, blood glucose monitoring, insulin therapy as needed)
Trial: 12093058
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose amiodarone (200 mg/day)
Trial: 9811284
Drug: Hydrogel moist
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel moist wound dressing (Elasto-gel)
Trial: 9811284
Drug: Breast shells
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast shells and lanolin cream
Trial: 7658603
Drug: Soy oligosaccharide
RxNorm normalized name: chitosan oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy oligosaccharide fiber (75 g/L)
Trial: 7658603
Drug: Soy polysaccharide
RxNorm normalized name: Soy polysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy polysaccharide fiber (20 g/L)
Trial: 7658603
Drug: Oat fiber
RxNorm normalized name: Oat fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat fiber (15 g/L)
Trial: 2704504
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen (Premarin) + 5 mg medroxyprogesterone acetate (Provera)
Trial: 2704504
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg conjugated equine estrogen (Premarin) + 5 mg medroxyprogesterone acetate (Provera)
Trial: 2704504
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen (Premarin) + placebo
Trial: 2704504
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg conjugated equine estrogen (Premarin) + placebo
Trial: 407817
Drug: Oral cromolyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cromolyn therapy
Trial: 31321541
Drug: CGRP-targeted treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP-targeted treatments
Trial: 27761732
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg vaginal progesterone suppository twice daily
Trial: 27761732
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral dydrogesterone twice daily
Trial: 27761732
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral dydrogesterone twice daily combined with 0.1 mg GnRH‐α
Trial: 27761732
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral dydrogesterone twice daily combined with 1500 IU hCG
Trial: 25345840
Drug: Intralesional bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intralesional bevacizumab with antiretroviral therapy
Trial: 25345840
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy alone (Control)
Trial: 23539110
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) dosing strategy
Trial: 21594828
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration (Hep [+])
Trial: 21594828
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin administration (Hep [‐])
Trial: 19155456
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 to 20 mg/d for 12 weeks)
Trial: 11277342
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor therapy (enalapril maleate, imidapril hydrochloride, trandolapril)
Trial: 27743129
Drug: 4-h Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-h Oral Fat Tolerance Test (OFTT) without prior exercise
Trial: 27743129
Drug: 4-h Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-h Oral Fat Tolerance Test (OFTT) with 1-h prior aerobic exercise
Trial: 27093772
Drug: Oral-B 3D
RxNorm normalized name: Oral-B 3D White Luxe Pulsar Toothbrush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B 3D White Radiant
Trial: 25300874
Drug: Multicomponent online
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent online sleep intervention (sleep information, sleep hygiene education, cognitive behavioral therapy)
Trial: 17576075
Drug: Hypnotic induction
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic induction by audiotape
Trial: 17576075
Drug: Hypnotic induction
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic induction live
Trial: 8416406
Drug: Full-strength acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-strength acellular pertussis vaccine (40 micrograms of pertussis proteins)
Trial: 8416406
Drug: Half-strength acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-strength acellular pertussis vaccine
Trial: 8416406
Drug: Quarter-strength acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarter-strength acellular pertussis vaccine
Trial: 8416406
Drug: Standard adult
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adult tetanus-diphtheria vaccine alone
Trial: 3816923
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg controlled release (CR) tablets of salbutamol b.d.
Trial: 3816923
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg conventional tablets of salbutamol a.i.d.
Trial: 31975122
Drug: VEPTR surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEPTR surgery with administration of preoperative antibiotics more than 30 minutes before surgery (or >60 minutes for vancomycin)
Trial: 31975122
Drug: VEPTR implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEPTR implant surgeries
Trial: 10657270
Drug: Inhaled carbon
RxNorm normalized name: carbon dioxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled carbon dioxide (CO2)
Trial: 8866596
Drug: Dose‐titrated slow‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose‐titrated slow‐release theophylline capsules ('Theo‐Dur') b.i.d. (n=97)
Trial: 29861050
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy (CRT) with normal PTF‐V1
Trial: 29861050
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy (CRT) with abnormal PTF‐V1
Trial: 17656473
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements with IDPN
Trial: 17656473
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements without IDPN
Trial: 17656473
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in prealbumin >30 mg/L within 3 months
Trial: 11870174
Drug: High-dose adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adjuvant interferon alfa-2b (IFNα2b)
Trial: 10192568
Drug: Drain kept
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drain kept until discharge had decreased to less than 35 ml/24 hours
Trial: 7491817
Drug: PFP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFP vaccine
Trial: 7491817
Drug: TIV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIV vaccine (control)
Trial: 2176794
Drug: pH-adjusted 1.73%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-adjusted 1.73% lidocaine (1 ml of NaHCO3 44.6 meq/L added to 10 ml of 2% lidocaine hydrochloride)
Trial: 21356042
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment (warfarin for 6 months followed by antiplatelet agents)
Trial: 11419834
Drug: IFN-alpha-2A (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha-2A (subcutaneous injections)
Trial: 3816835
Drug: Labetalol (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (loading dose followed by slow intravenous infusion over six hours, then oral therapy for five days, adjusted to maintain systolic pressure 100-120 mmHg)
Trial: 29336835
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (77 Gy in 35 fractions)
Trial: 29336835
Drug: Dose-escalated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated treatment (77 Gy in 35 fractions + integrated boost up to 95 Gy)
Trial: 24278929
Drug: Osstem TSIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osstem TSIII HA implants (4.5 or 5.0 mm diameter, 10 mm long)
Trial: 24278929
Drug: Zimmer TSV
RxNorm normalized name: BINDER,ABDOMINAL,10IN ZIMMER #2732-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimmer TSV implants (4.7 mm diameter, 10 mm long)
Trial: 18219661
Drug: Gefitinib (treatment)
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib (treatment)
Trial: 18219661
Drug: Zymed antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zymed antibody (treatment)
Trial: 10351414
Drug: New medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New medication for osteoarthritis
Trial: 7743286
Drug: 5% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lignocaine ointment applied to the heel under an occlusive dressing for one hour before heel prick
Trial: 7138632
Drug: Potassium and
RxNorm normalized name: Potassium and/or potassium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium and magnesium aspartate (K + Mg Asp) - 7.2 g administered during a 24 h period prior to work
Trial: 7138632
Drug: Potassium and
RxNorm normalized name: Potassium and/or potassium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium and magnesium aspartate (K + Mg Asp)
Trial: 30633959
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) 50 ppm for 24 hours
Trial: 26591552
Drug: Pioglitazone as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone as part of combination therapy for 3 months
Trial: 21528639
Drug: Eplerenone 50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg (test formulation)
Trial: 19358416
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with a cytotoxic platinum agent
Trial: 19358416
Drug: Cytotoxic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic agents alone
Trial: 12507703
Drug: ADL 10‐0101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADL 10‐0101 (peripherally selective KOR agonist)
Trial: 9011784
Drug: Multiple-allergen immunotherapy
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-allergen immunotherapy (subcutaneous injections of a mixture of up to seven aeroallergen extracts)
Trial: 9011784
Drug: Placebo (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous injections of placebo)
Trial: 9011784
Drug: Multiple-allergen immunotherapy
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-allergen immunotherapy
Trial: 3124427
Drug: Doxycycline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (400 mg in a single dose)
Trial: 3124427
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g given twice with an 8-hour interval)
Trial: 30541221
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg) 20 min before anesthesia induction, followed by 0.2 μg·kg(‐1)·h(‐1) intraoperatively.
Trial: 30541221
Drug: Dexmedetomidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.1 μg·kg(‐1)·h(‐1)) plus sufentanil (0.025 μg·kg(‐1)·h(‐1)) for PCA in group D.
Trial: 25412051
Drug: Fascia iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca compartment block with catheter placement and continuous infusion
Trial: 24694531
Drug: Evolocumab 140
RxNorm normalized name: evolocumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 140 mg Q2W
Trial: 24694531
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg QM
Trial: 23713082
Drug: BAY 94‐8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 94‐8862 (5-10 mg/day)
Trial: 23713082
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 or 50 mg/day)
Trial: 19132268
Drug: Agaricus sylvaticus
RxNorm normalized name: AGARICUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agaricus sylvaticus fungus (30 mg/kg/day)
Trial: 29770722
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 0.1% ointment
Trial: 16629794
Drug: Cetomacrogol ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetomacrogol ointment (placebo)
Trial: 14636982
Drug: Artesunate alone
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate alone (50 mg rectal capsules, 40 mg/kg total dose over 6 days)
Trial: 14636982
Drug: Artesunate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (50 mg rectal capsules, 30 mg/kg total dose for 3 days) + Mefloquine (20 mg/kg total dose on day 1)
Trial: 14636982
Drug: Artesunate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (50 mg rectal capsules, 30 mg/kg total dose for 3 days) + Mefloquine (15-17 mg/kg total dose on days 1 and 3)
Trial: 8672384
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine and adrenaline 1/200,000 (B+E) 8 ml before incision and saline 8 ml after incision
Trial: 8672384
Drug: Saline 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 8 ml before incision and B+E 8 ml after incision
Trial: 8672384
Drug: Saline 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 8 ml before and after incision
Trial: 30689969
Drug: Trial group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial group with additional intraoperative splint for verification of implants' angulation
Trial: 12858407
Drug: Anti-HCV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-HCV treatment in HIV-coinfected patients
Trial: 9796763
Drug: Colchicine treatment
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine treatment for 8 weeks
Trial: 19863619
Drug: FPV 1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV 1400 mg bid with TDF 300 mg qd
Trial: 19863619
Drug: FPV/RTV 700/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV/RTV 700/100 mg bid with TDF 300 mg qd
Trial: 19863619
Drug: FPV 1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV 1400 mg bid without TDF
Trial: 19863619
Drug: FPV/RTV 700/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV/RTV 700/100 mg bid without TDF
Trial: 12893904
Drug: Undiluted direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undiluted direct injection of ferumoxides (0.56 mg of iron per kg of body weight, administered during 2 minutes at 2 mL/min)
Trial: 12893904
Drug: Diluted slow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted slow infusion of ferumoxides (administered during 30 minutes)
Trial: 12893904
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (direct injection and slow infusion)
Trial: 10589310
Drug: teacher/self-preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: teacher/self-preparation
Trial: 10589310
Drug: nurse/self-preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nurse/self-preparation
Trial: 9005789
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg intravenous followed by 400 mg oral once a day for at least 14 days
Trial: 9005789
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg oral once a day
Trial: 9005789
Drug: Ofloxacin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (various regimens: 200 mg thrice a day, 200 mg twice a day, 400 mg once a day)
Trial: 6781586
Drug: 50 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 (low dose)
Trial: 6781586
Drug: 500 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/m2 (medium dose)
Trial: 6781586
Drug: 5 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/m2 (high dose)
Trial: 6781586
Drug: Cross-over to
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-over to higher dose